News · 26 weeks49-36%
2025-11-022026-04-26
Mix2990d
- Insider15(52%)
- SEC Filings6(21%)
- Other4(14%)
- Earnings3(10%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Establishment Labs Holdings Inc.DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® to Announce First Quarter 2026 Financial Results on May 6Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Est
- INSIDERSEC Form 4 filed by Chacon Quiros Juan Jose4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECSEC Form DEFA14A filed by Establishment Labs Holdings Inc.DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- SECSEC Form DEF 14A filed by Establishment Labs Holdings Inc.DEF 14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Caldini Filippo4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- PREstablishment Labs® Surpasses More Than Five Million Motiva® Devices in MarketEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction solutions across more than 100 countries worldwide. "Surpassing five million Motiva devices is another milestone for our company, and a clear reflection that our investment in bringing better technology and procedures to mar
- INSIDERSEC Form 4 filed by Schutter Edward J4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Gillin Leslie4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Slotkin Bryan4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Lewin Nicholas Sheridan4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Schutter Edward J4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Custin Ann4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Chacon Quiros Juan Jose4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Chacon Quiros Juan Jose4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERChief Financial Officer Harris Cassandra was granted 7,372 shares (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 3 filed by new insider Harris Cassandra3 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERGeneral Counsel and CCO Mansbach Samuel Ross covered exercise/tax liability with 657 shares, decreasing direct ownership by 3% to 18,663 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERGeneral Counsel and CCO Mansbach Samuel Ross was granted 4,082 shares, increasing direct ownership by 27% to 19,320 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERChief Executive Officer Caldini Filippo was granted 8,185 shares, increasing direct ownership by 23% to 43,430 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECSEC Form S-8 filed by Establishment Labs Holdings Inc.S-8 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- SECSEC Form 10-K filed by Establishment Labs Holdings Inc.10-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- SECEstablishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs Announces Leadership Transition to Support Next Phase of GrowthEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum
- PREstablishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 GuidanceEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compa
ESTA FAQ
7 questionsWhat does Establishment Labs Holdings Inc. do?
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through...Where does ESTA stock trade?
Establishment Labs Holdings Inc. (ESTA) is listed on NASDAQ.What sector and industry is ESTA in?
Establishment Labs Holdings Inc. operates in the Health Care sector, Industrial Specialties industry.When did Establishment Labs Holdings Inc. go public?
Establishment Labs Holdings Inc. (ESTA) completed its IPO in 2018.What are analysts saying about ESTA?
Establishment Labs Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2025-08-20. Recent price targets cluster around $4800.00.What companies are similar to ESTA?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare ESTA side-by-side with any of them on Quantisnow.How can I track ESTA on Quantisnow?
Quantisnow aggregates Establishment Labs Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESTA to receive live email and push alerts on every new disclosure.